Clinical Trial Outcomes Uncertainty: Calcimedica's drug candidates must successfully complete extensive clinical trials, and there is a significant risk that these trials may fail to demonstrate efficacy or safety, or be delayed, preventing product approval and commercialization.

Regulatory Approval Risks: Even with positive clinical trial results, obtaining necessary regulatory approvals from agencies like the FDA is a lengthy, complex, and uncertain process, which could delay or prevent market entry for Calcimedica's products.

Capital Funding Requirements: Developing biopharmaceutical products is capital-intensive, and Calcimedica may require substantial additional financing to fund its research, development, and commercialization efforts, which may not be available on favorable terms or at all.